Meeder Advisory Services Inc. Takes Position in Moderna, Inc. $MRNA

Meeder Advisory Services Inc. purchased a new stake in shares of Moderna, Inc. (NASDAQ:MRNA) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 7,734 shares of the company’s stock, valued at approximately $542,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in Moderna by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 41,584,782 shares of the company’s stock worth $1,226,335,000 after acquiring an additional 399,487 shares in the last quarter. BlackRock Inc. bought a new position in shares of Moderna during the second quarter valued at approximately $2,142,877,000. Capital World Investors purchased a new position in shares of Moderna during the fourth quarter valued at approximately $378,299,000. Invesco Ltd. lifted its holdings in shares of Moderna by 15.7% during the third quarter. Invesco Ltd. now owns 8,216,163 shares of the company’s stock valued at $212,223,000 after purchasing an additional 1,115,131 shares during the last quarter. Finally, Theleme Partners LLP boosted its position in shares of Moderna by 8.6% in the 2nd quarter. Theleme Partners LLP now owns 7,868,810 shares of the company’s stock worth $217,100,000 after purchasing an additional 626,420 shares in the last quarter. 75.33% of the stock is owned by hedge funds and other institutional investors.

More Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Phase 3 melanoma success validates Moderna’s mRNA platform. Moderna and Merck said their personalized cancer vaccine, intismeran autogene, combined with Keytruda, met both recurrence-free-survival and distant-metastasis-free-survival endpoints in high-risk, fully resected Stage IIB-IV melanoma patients. The result is described as the first positive late-stage trial for a personalized mRNA cancer vaccine and could support regulatory filings as early as 2027. Merck and Moderna Phase 3 trial announcement
• Positive Sentiment: Investors see potential beyond COVID-19 vaccines. Analysts believe a successful personalized oncology product could establish a major new revenue stream and raise the value of Moderna’s broader cancer pipeline, including programs targeting lung, kidney and bladder cancers. Jefferies estimated potential global peak sales of approximately $54 billion and raised its price target to $170, while other estimates were more conservative. Moderna oncology platform draws Street value
• Neutral Sentiment: The sharp move was amplified by a short squeeze. Reports estimate that short sellers faced billions of dollars in mark-to-market losses after the trial news, forcing some to buy shares to cover positions. This technical support can intensify gains but may not represent sustained fundamental demand. Moderna short-sellers report
• Negative Sentiment: Profit-taking and valuation concerns are driving the pullback. The stock’s earlier surge priced in substantial success, and several analysts’ revised targets remained below the prevailing market price. Morgan Stanley raised its target but maintained an equal-weight rating, citing limited near-term upside. Moderna valuation concerns
• Negative Sentiment: Important risks remain. Moderna has released topline results, but investors are awaiting detailed data, regulatory review and eventual commercialization. Doctors and analysts have also cautioned that enthusiasm may be running ahead of the evidence, leaving the shares vulnerable to further volatility. Moderna personalized mRNA shot analysis

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. William Blair upgraded Moderna from a “market perform” rating to an “outperform” rating in a research note on Wednesday. Jefferies Financial Group reissued a “hold” rating on shares of Moderna in a report on Wednesday. Morgan Stanley increased their target price on Moderna from $39.00 to $89.00 and gave the stock an “equal weight” rating in a research note on Thursday. UBS Group increased their target price on Moderna from $50.00 to $150.00 and gave the stock a “neutral” rating in a research note on Thursday. Finally, Piper Sandler restated an “overweight” rating on shares of Moderna in a report on Monday, August 3rd. Four research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and four have assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $66.25.

Moderna Stock Down 23.5%

Moderna stock opened at $133.32 on Friday. Moderna, Inc. has a 12 month low of $22.28 and a 12 month high of $176.66. The stock has a fifty day simple moving average of $66.58 and a two-hundred day simple moving average of $55.47. The company has a current ratio of 2.29, a quick ratio of 2.18 and a debt-to-equity ratio of 0.09. The firm has a market cap of $53.23 billion, a price-to-earnings ratio of -16.69 and a beta of 0.91.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Friday, July 31st. The company reported ($1.97) EPS for the quarter, beating the consensus estimate of ($2.03) by $0.06. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%.The company had revenue of $145.00 million for the quarter, compared to analysts’ expectations of $102.93 million. During the same period last year, the firm posted ($2.13) earnings per share. Moderna’s revenue was up 2.1% compared to the same quarter last year. Equities analysts predict that Moderna, Inc. will post -6.18 EPS for the current fiscal year.

Insider Transactions at Moderna

In other news, President Stephen Hoge sold 53,336 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $51.37, for a total transaction of $2,739,870.32. Following the completion of the transaction, the president directly owned 1,483,848 shares of the company’s stock, valued at $76,225,271.76. The trade was a 3.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Thyme Klinger sold 3,471 shares of the stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $50.00, for a total transaction of $173,550.00. Following the transaction, the insider owned 67,468 shares in the company, valued at approximately $3,373,400. This trade represents a 4.89% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 10.80% of the company’s stock.

Moderna Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.